What the warning says
Section 5.2 of the US label states that acute pancreatitis, including fatal and non-fatal haemorrhagic or necrotising forms, has been observed with GLP-1 medicines including liraglutide. [1] Once Victoza® has been started, prescribers are asked to look out for belly pain that is persistent or severe, may travel through to the back and may or may not come with nausea or vomiting, and to stop Victoza® if pancreatitis is suspected. [1] Canada adds that the watch applies after dose increases as well, that the pain may be persistent or come and go, and that other suspect medicines should also be stopped. [3]
Europe goes one step further on what happens next: if acute pancreatitis is confirmed, liraglutide should not be restarted. [2] Canada says the same. [3]
The trial cases
Across the glycemic control trials, 13 people on Victoza® and 1 on glimepiride developed pancreatitis: 9 of the 13 were acute and 4 chronic. [1] One person on Victoza® had necrotising pancreatitis and died, but the label says clinical causality could not be established, and some patients had other risk factors such as a history of gallstones or alcohol misuse. [1] The European summary reports acute pancreatitis in fewer than 0.2% across its long-term phase 3 trials and rates pancreatitis as very rare overall. [2]
| Measure | Victoza® | Comparison group |
|---|---|---|
| Pancreatitis cases, glycemic trials | 13 (2.7 per 1,000 patient-years) | 1 on glimepiride (0.5) |
| Lipase ≥3 × upper limit, LEADER | 7.9% | 4.5% on placebo |
| Amylase ≥3 × upper limit, LEADER | 1% | 0.7% on placebo |
LEADER: the longest look
LEADER followed 9,340 adults with type 2 diabetes at high cardiovascular risk for a median of 3.8 years, measured fasting lipase and amylase routinely and had suspected pancreatitis judged by a blinded committee. [4] Confirmed acute pancreatitis occurred in 18 people on liraglutide (1.1 per 1,000 patient-years) and 23 on placebo (1.7). [3][4] There were no confirmed chronic cases on liraglutide and 2 on placebo. [3] Most acute cases occurred 12 months or more after randomisation. [4] Europe reports the same comparison as 0.4% against 0.5%. [2]
LEADER also included 267 people with a history of pancreatitis. A new confirmed episode occurred in 2 of 147 on liraglutide and 6 of 120 on placebo. [3] Canada still notes that only a limited number of such patients have been studied, and that it is not known whether they are at higher risk on Victoza®. [3]
Enzyme results without symptoms
Lipase and amylase are blood tests used to diagnose pancreatitis, so a raised result on Victoza® can be alarming. In LEADER, liraglutide raised lipase by 28% and amylase by 7% on average compared with placebo; levels rose within 6 months and then stayed stable. [4] Elevations did not predict later pancreatitis, with a positive predictive value below 1%. [4] Canada reports mean increases of up to 38% and 21% and says they were not predictive. [3] The US label states that the clinical significance of raised enzymes without other signs of pancreatitis is unknown. [1]
Europe lists raised lipase and amylase as common findings in trials where they were measured. [2]
What meta-analyses conclude
A 2017 meta-analysis of 113 randomised trials in type 2 diabetes, including the large cardiovascular outcome trials, found no significant difference in pancreatitis between GLP-1 medicines and comparators (odds ratio 0.93). [5] A 2025 meta-analysis of 62 trials across GLP-1 medicines estimated a modest overall increase (relative risk 1.44), which was no longer significant when trials were analysed by background medication. [6] Its authors also note that many trials with zero events in both arms could not be included. [6] Taken together, the evidence suggests any added risk is small, which is why the warning focuses on recognising symptoms.
Why it might happen
Label position: the labels describe the observations and the response, not a mechanism. [1][2]
Not established: the rise in lipase and amylase shows that liraglutide affects the pancreas’s enzyme output, but LEADER found no link between those rises and later pancreatitis. [4]
A possible indirect route: MedlinePlus names gallstones as the most common cause of acute pancreatitis, and Victoza® raised acute gallbladder events in LEADER. [7][1] No source in this page measured whether that chain explains any pancreatitis cases on Victoza®.
Other causes of pancreatitis
MedlinePlus lists gallstones and alcohol as leading causes, followed by very high triglycerides, injury or surgery to the pancreas, procedures such as ERCP, cystic fibrosis, an overactive parathyroid gland, infections such as mumps and certain medicines, including some estrogens, corticosteroids and thiazide diuretics. [7] The US label notes that some of the trial cases on Victoza® had gallstones or alcohol misuse in their history. [1]
The symptom that means stop and call
- Stop Victoza® and phone your provider at once if severe abdominal pain persists, whether or not you vomit; the Medication Guide notes it may be felt through to the back. [1]
- MedlinePlus describes the pain as upper left or middle abdominal pain that can worsen soon after eating, become constant and severe, and be worse lying flat; fever, nausea, vomiting and sweating are common. [7]
- Before starting, tell your provider if you have or have had problems with your pancreas. [1]
- MedlinePlus says avoiding alcohol when it is the likely cause, not smoking and treating high triglycerides can lower the chance of repeat attacks. [7]
- If pancreatitis is confirmed, Europe and Canada say liraglutide should not be restarted; this is a decision for your prescriber. [2][3]
Victoza® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk A/S.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Severe stomach pain that will not go away, possibly spreading to the back, with or without vomiting | Stop Victoza® and call your provider immediately; emergency care if severe | Emergency | Medication Guide [1]; Canadian patient information [3] |
| Intense, constant upper belly pain with fever, a fast pulse or sweating | Emergency care | Emergency | MedlinePlus [7] |
| Pain that comes and goes in the upper abdomen after a dose increase | Your provider, the same day | Today | Canadian monograph [3] |
| A raised lipase or amylase result without symptoms | Discuss with your prescriber | At your next appointment | US label section 6.1 [1]; Steinberg 2017 [4] |
| A past episode of pancreatitis before starting Victoza® | Tell your prescriber before the first dose | At your next appointment | Medication Guide [1] |
